Analysts Set iCAD, Inc. (NASDAQ:ICAD) Price Target at $16.50

iCAD, Inc. (NASDAQ:ICAD – Get Rating) has received a consensus recommendation of “Hold” from the seven analysts that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $16.50.

Several equities research analysts recently weighed in on the company. StockNews.com started coverage on iCAD in a report on Thursday, March 31st. They issued a “hold” rating for the company. Lake Street Capital reduced their target price on shares of iCAD from $22.00 to $13.00 in a research note on Tuesday, March 1st. Finally, Zacks Investment Research cut shares of iCAD from a “hold” rating to a “sell” rating in a research note on Tuesday, May 17th.

In other iCAD news, Director Timothy Norris Irish acquired 5,500 shares of the company’s stock in a transaction that occurred on Thursday, March 3rd. The stock was bought at an average price of $4.63 per share, with a total value of $25,465.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 12.50% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently modified their holdings of the company. ACT Capital L.L.C. raised its stake in iCAD by 1.1% in the third quarter. ACT Capital L.L.C. now owns 224,500 shares of the technology company’s stock valued at $2,413,000 after purchasing an additional 2,500 shares in the last quarter. Citigroup Inc. grew its position in iCAD by 127.2% in the fourth quarter. Citigroup Inc. now owns 5,572 shares of the technology company’s stock worth $40,000 after acquiring an additional 3,120 shares in the last quarter. BNP Paribas Arbitrage SA increased its stake in iCAD by 324.2% in the third quarter. BNP Paribas Arbitrage SA now owns 4,119 shares of the technology company’s stock valued at $44,000 after acquiring an additional 3,148 shares during the last quarter. Geode Capital Management LLC raised its position in iCAD by 1.0% during the fourth quarter. Geode Capital Management LLC now owns 378,245 shares of the technology company’s stock valued at $2,723,000 after purchasing an additional 3,811 shares in the last quarter. Finally, Rhumbline Advisers lifted its stake in iCAD by 26.9% during the first quarter. Rhumbline Advisers now owns 19,635 shares of the technology company’s stock worth $88,000 after purchasing an additional 4,159 shares during the last quarter. 48.53% of the stock is owned by institutional investors.

ICAD opened at $3.61 on Friday. iCAD has a twelve month low of $2.91 and a twelve month high of $19.00. The company’s 50-day moving average price is $3.77 and its two-hundred day moving average price is $5.42. The stock has a market cap of $90.91 million, a price-to-earnings ratio of -6.81 and a beta of 1.28.

iCAD (NASDAQ:ICAD – Get Rating) last posted its quarterly earnings data on Wednesday, May 11th. The technology company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.04). The firm had revenue of $7.52 million during the quarter, compared to analysts’ expectations of $7.50 million. iCAD had a negative net margin of 40.43% and a negative return on equity of 26.45%. On average, sell-side analysts expect that iCAD will post -0.57 EPS for the current year.

iCAD Company Profile (Get Rating)

iCAD, Inc provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment.

Featured Stories